ICU Medical (NASDAQ:ICUI) Raised to “Buy” at Wall Street Zen

ICU Medical (NASDAQ:ICUI) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Several other analysts have also recently issued reports on the stock. KeyCorp upped their price objective on shares of ICU Medical from $173.00 to $175.00 and gave the company an “overweight” rating in a research note on Friday, November 7th. Piper Sandler upped their price target on ICU Medical from $153.00 to $172.00 and gave the company an “overweight” rating in a research report on Friday, November 7th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ICU Medical in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $175.67.

ICU Medical Stock Down 2.9%

NASDAQ ICUI opened at $138.53 on Friday. The business has a fifty day moving average price of $140.11 and a 200 day moving average price of $130.74. ICU Medical has a one year low of $107.00 and a one year high of $175.51. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.19 and a current ratio of 2.45. The company has a market cap of $3.42 billion, a P/E ratio of -446.86 and a beta of 0.80.

ICU Medical (NASDAQ:ICUI) last announced its earnings results on Thursday, November 6th. The medical instruments supplier reported $2.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.43 by $0.60. The company had revenue of $533.30 million for the quarter, compared to analysts’ expectations of $511.46 million. ICU Medical had a negative net margin of 0.32% and a positive return on equity of 7.71%. The firm’s quarterly revenue was down 8.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.59 EPS. ICU Medical has set its FY 2025 guidance at 7.350-7.650 EPS. Research analysts anticipate that ICU Medical will post 4.11 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Elisha W. Finney sold 1,285 shares of the stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of $140.42, for a total value of $180,439.70. Following the completion of the transaction, the director directly owned 3,995 shares in the company, valued at approximately $560,977.90. This represents a 24.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Virginia Ruth Sanzone sold 930 shares of the firm’s stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $142.34, for a total value of $132,376.20. Following the sale, the vice president directly owned 5,456 shares of the company’s stock, valued at approximately $776,607.04. This trade represents a 14.56% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of ICU Medical

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Cullen Frost Bankers Inc. acquired a new position in ICU Medical in the second quarter valued at about $38,000. SJS Investment Consulting Inc. raised its stake in shares of ICU Medical by 41,000.0% in the 3rd quarter. SJS Investment Consulting Inc. now owns 411 shares of the medical instruments supplier’s stock valued at $49,000 after acquiring an additional 410 shares during the period. Covestor Ltd lifted its holdings in shares of ICU Medical by 70.7% in the 3rd quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after acquiring an additional 236 shares during the last quarter. Blue Trust Inc. boosted its position in shares of ICU Medical by 17.6% during the 2nd quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after purchasing an additional 141 shares during the period. Finally, Smartleaf Asset Management LLC boosted its position in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after purchasing an additional 101 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.